Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. by St John Sutton, Martin et al.
Cardiac resynchronization induces major structural and
functional reverse remodeling in patients with New York
Heart Association class I/II heart failure.
Martin St John Sutton, Stefano Ghio, Ted Plappert, Luigi Tavazzi, Laura
Scelsi, Claude Daubert, William T Abraham, Michael R Gold, Christian
Hassager, John M Herre, et al.
To cite this version:
Martin St John Sutton, Stefano Ghio, Ted Plappert, Luigi Tavazzi, Laura Scelsi, et al.. Cardiac
resynchronization induces major structural and functional reverse remodeling in patients with
New York Heart Association class I/II heart failure.. Circulation, American Heart Association,
2009, 120 (19), pp.1858-65. <10.1161/CIRCULATIONAHA.108.818724>. <hal-00913616>
HAL Id: hal-00913616
https://hal.archives-ouvertes.fr/hal-00913616
Submitted on 4 Jun 2014
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Cardiac Resynchronization Induces Major Structural and
Functional Reverse Remodeling in Patients With New York
Heart Association Class I/II Heart Failure
Martin St. John Sutton, MB, FRCP; Stefano Ghio, MD; Ted Plappert, CVT;
Luigi Tavazzi, MD, FESC; Laura Scelsi, MD; Claude Daubert, MD; William T. Abraham, MD;
Michael R. Gold, MD, PhD; Christian Hassager, MD, PhD;
John M. Herre, MD; Cecilia Linde, MD, PhD; on Behalf of the REsynchronization reVErses
Remodeling in Systolic left vEntricular dysfunction (REVERSE) Study Group
Background—Cardiac resynchronization therapy (CRT) improves LV structure, function, and clinical outcomes in New
York Heart Association class III/IV heart failure with prolonged QRS. It is not known whether patients with New York
Heart Association class I/II systolic heart failure exhibit left ventricular (LV) reverse remodeling with CRT or whether
reverse remodeling is modified by the cause of heart failure.
Methods and Results—Six hundred ten patients with New York Heart Association class I/II heart failure, QRS duration
$120 ms, LV end-diastolic dimension $55 mm, and LV ejection fraction #40% were randomized to active therapy
(CRT on; n5419) or control (CRT off; n5191) for 12 months. Doppler echocardiograms were recorded at baseline,
before hospital discharge, and at 6 and 12 months. When CRT was turned on initially, immediate changes occurred in
LV volumes and ejection fraction; however, these changes did not correlate with the long-term changes (12 months) in
LV end-systolic (r50.11, P50.31) or end-diastolic (r50.10, P50.38) volume indexes or LV ejection fraction (r50.07,
P50.72). LV end-diastolic and end-systolic volume indexes decreased in patients with CRT turned on (both P,0.001
compared with CRT off), whereas LV ejection fraction in CRT-on patients increased (P,0.0001 compared with CRT
off) from baseline through 12 months. LV mass, mitral regurgitation, and LV diastolic function did not change in either
group by 12 months; however, there was a 3-fold greater reduction in LV end-diastolic and end-systolic volume indexes
and a 3-fold greater increase in LV ejection fraction in patients with nonischemic causes of heart failure.
Conclusions—CRT in patients with New York Heart Association I/II resulted in major structural and functional reverse
remodeling at 1 year, with the greatest changes occurring in patients with a nonischemic cause of heart failure. CRT may
interrupt the natural disease progression in these patients.
Clinical Trial Registration—Clinicaltrials.gov Identifier: NCT00271154. (Circulation. 2009;120:1858-1865.)
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Cardiac resynchronization is an established therapy foradvanced heart failure (HF) because it prolongs survival,
improves symptoms, and increases exercise capacity in pa-
tients with HF (New York Heart Association [NYHA] class
III/IV), left ventricular ejection fraction (LVEF) #35%, and
QRS duration $120 ms.1–5 The salutary effects of cardiac
resynchronization therapy (CRT) in patients with HF that is
refractory to optimal medical treatment are associated with
structural and functional left ventricular (LV) reverse
remodeling.
Editorial see p 1845
Clinical Perspective on p 1865
We hypothesized that CRT would result in LV reverse
remodeling in NYHA class I and II HF patients that may
delay disease progression to class III/IV. The specific aims of
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this prospective study were to determine whether patients
with NYHA class I/II systolic HF exhibited LV reverse
remodeling with CRT at 1 year, and if so, whether this reverse
remodeling was modified by the cause of HF.
Methods
The REsynchronization reVErses Remodeling in Systolic left
vEntricular dysfunction (REVERSE) study was a randomized,
double-blind, controlled trial of CRT in patients with NYHA class
I/II HF for at least 3 months before enrollment. All patients were in
sinus rhythm with QRS duration $120 ms, LVEF #40%, and LV
end-diastolic dimension $55 mm. Patient inclusion and exclusion
criteria have been published previously.6 All patients were receiving
optimal medical HF therapy, which included stable doses of an
angiotensin-converting enzyme inhibitor or angiotensin II receptor
blocker for a minimum of 1 month and a b-adrenergic receptor
blocker for at least 3 months.7,8 The ethics committee at each
investigator site approved the protocol, and all patients gave written
informed consent.
After baseline evaluation, patients underwent implantation of a
CRT device with or without implantable cardioverter defibrillator
capabilities and were then randomly assigned in a 2:1 model to active
(CRT-ON) or control (CRT-OFF) conditions for 12 months. Two-
dimensional, M-mode, and Doppler echocardiograms were recorded
with an ECG at baseline, before hospital discharge (PHD), and at 6
and 12 months. Patients underwent 2 echocardiographic examina-
tions at PHD and 2 echocardiographic examinations at 12 months. At
PHD, the first echocardiogram was performed with CRT pro-
grammed off and the second with it programmed on after the device
was optimized. The devices were then programmed according to the
patients’ randomization assignments. At 12-month follow-up, the
first of the 2 echocardiograms was performed with CRT programmed
on for patients randomized to CRT-ON, after which they underwent
a 10-minute washout with CRT turned off before a second echocar-
diogram was performed with the CRT programmed off. The 10-
minute washout period was to minimize any potential effect of CRT
on LV loading conditions and therefore on LV volumes and LVEF.
Likewise, at 12-month follow-up, patients randomized to CRT-OFF
had the first echocardiogram performed with CRT programmed off
and then the second with it programmed on.
The rationale for recording 2 echocardiograms at PHD with
opposite programming was to determine whether immediate changes
in LV volumes and LVEF predicted the changes in LV volume and
LVEF at 12 months. The rationale for obtaining 2 echocardiograms
at 12 months was to demonstrate that changes in LV volumes did not
revert to baseline values when the CRT device was turned off but
were sustained, reflecting true reverse remodeling at 1 year.
Patients assigned to CRT-ON were programmed to a mode that
paced both ventricles and inhibited atrial pacing unless the intrinsic
rate was #35 bpm. Patients assigned to CRT-OFF had the device
programmed to inhibit atrial or ventricular pacing unless the intrinsic
heart rate was #35 bpm. The time delay between atrial sensed
activity and delivery of simultaneous biventricular pacing (AV
delay) was optimized to maximize LV filling time without truncating
left atrial contraction.9
Echocardiograms were analyzed in a core laboratory that was not
informed of the randomization assignment. LV dimensions were
recorded with 2D-directed M-mode echocardiography at the tips of
the mitral valve leaflets. Echocardiograms were digitized to obtain
LV volumes by Simpson’s method of discs, as recommended by the
American Society of Echocardiography,10 from which LVEF was
calculated. LV shape was computed at end diastole as the ratio of LV
volume to the volume of a sphere with a diameter equal to LV cavity
length in the apical 4-chamber view.11 LV mass was calculated at
end diastole as: [5/63LV short-axis myocardial area3LV
length31.055] (1.0555the density of myocardium). The severity of
mitral regurgitation (MR) was assessed from orthogonal apical
echocardiographic images as the average area (measured by planim-
etry) of the Doppler color-encoded mitral regurgitant jet within the
left atrium.
Transmitral Doppler signals were digitized to obtain the peak
E-wave and peak A-wave velocities and deceleration time of the E
wave. The myocardial performance index was calculated as the sum
of isovolumic contraction time and isovolumic relaxation time
divided by LV ejection time.12 Interventricular mechanical delay
(IVMD) was used as an indicator of interventricular dyssynchrony,
defined as the time interval between the onset of antegrade blood
flow in the right ventricular outflow tract and in the LV outflow tract.
IVMD was estimated from the respective pulsed-wave Doppler
velocity signals. QRS duration was used as an indicator of global LV
dyssynchrony. Ischemic cardiomyopathy was defined as a history of
myocardial infarction, coronary revascularization, and 2- or 3-vessel
disease by coronary angiography, and nonischemic cardiomyopathy
was defined as the absence of these criteria.13
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Statistical Methods
All end points were analyzed with the subjects included in their
original randomized treatment group. All reported P values are
nominal, and all tests were 2-sided. All data reported are from
patients with analyzable echocardiograms. Where paired data were
required, only data from patients with both data points were used.
Echocardiographic parameters were measured as the absolute change
between baseline (performed before CRT implantation) and 12
months (performed as randomized) for comparison between the 2
randomized groups. Unless otherwise indicated, echocardiographic
data used in the analyses were collected with the patient’s device
programmed to the CRT mode to which the patient was randomized.
Correlations between short- and long-term changes were tested with
simple linear regression analysis. A 2-way ANOVA was used to
assess the effect of randomization along with cause of HF on specific
end points. P values that compared mean values of CRT-OFF versus
CRT-ON were calculated with a 2-sample t test. P values that
compared immediate changes were calculated with a paired t test.
Baseline comparisons between percentages of CRT-OFF and
CRT-ON patients were made with the Fisher exact test.
Results
A total of 684 patients were enrolled in the study, and a CRT
device was successfully implanted in 621 patients. Eleven
patients were not randomized for the following reasons:
Inclusion criteria not met, complete heart block, atrial ar-
rhythmias, LV lead dislodgment, loss of capture, death, HF
status (n52), and use of a surgical epicardial LV lead (n53).
Thus, the study population consisted of 610 patients, of
whom 419 were randomized to CRT-ON and 191 to CRT-
OFF. Baseline demographics were similar in the 2 groups
(Table 1), as described previously.14 Ninety-seven percent of
patients were taking either an angiotensin-converting enzyme
inhibitor or an angiotensin II receptor blocker, and 95% of
patients were taking a b-blocker, which indicates that medical
treatment was optimized in both groups.
For the overall population, mean LVEF was 26.767.0%,
and mean LV end-diastolic dimension was 6769 mm. The
mean QRS duration was 153622 ms. A CRT ICD was
implanted in 83% of patients, and a CRT device alone was
implanted in 17%.
Although REVERSE did not meet its primary end point of
HF clinical composite response,15 the study included LV
end-systolic volume index (LVESVi) as a prospectively
powered secondary end point and prespecified analyses to
assess changes in cardiac structure and function by
echocardiography.
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Paired baseline and 12-month echocardiograms at end
systole were available in 163 of 191 CRT-OFF and 340 of
419 CRT-ON patients. Reasons for missing data were as
follows (in chronological order; only the first reason was
counted): Echocardiography not performed at baseline (n51
CRT-OFF, n52 CRT-ON), a technically limited echocardio-
gram at baseline (n511 CRT-OFF, n531 CRT-ON), death
before the 12-month follow-up (n52 CRT-OFF, n59 CRT-
ON), echocardiography not performed at 12 months (n51
CRT-OFF, n58 CRT-ON), and a technically limited echo-
cardiogram at 12 months (n513 CRT-OFF, n529 CRT-ON).
Reverse Remodeling
Both LV end-diastolic volume index (LVEDVi) and LVESVi
decreased from baseline to 12 months in the CRT-ON group
compared with the CRT-OFF group (Figure 1; Table 2).
These changes in LV volumes in NYHA class I/II patients
were of similar magnitude to those reported in NYHA class
III/IV HF patients with CRT.2,16,17 Importantly, LV volumes
in the 2 groups in REVERSE diverged between PHD and 12
months. The changes in LV volumes over 12 months in the
CRT-ON group compared with the CRT-OFF group were
associated with improvement in LVEF (P,0.0001) and
restoration of LV cavity shape toward normal at end diastole
(P,0.01; Figure 1; Table 2). In spite of the significant
changes in LV volumes, shape, and ejection fraction in the
CRT-ON group, there was no accompanying change in mean
LV mass or severity of MR from baseline to 12 months
compared with the CRT-OFF group (Table 2).
To assess whether CRT permanently remodels the LV, the
changes in LVESVi, LVEDVi, and LVEF from baseline
(before CRT implantation) to 12 months with CRT pro-
grammed off and the change from PHD (when CRT was first
turned on temporarily in the CRT-OFF arm) to 12 months
with CRT turned on were analyzed (Table 3). In all compar-
isons, the CRT-ON group demonstrated a greater change
(P,0.0001) than the CRT-OFF group.
Paired measurements of LV dimensions by 2D-directed
M-mode echocardiography at baseline and 12 months in
control and active-treatment groups were available in approx-
imately 50% of patients. LV end-diastolic dimension and LV
end-systolic dimension decreased from baseline through 12
months in the CRT-ON group (P50.005 and P50.0004 at 12
months between groups, respectively; Table 2) but did not
change in the CRT-OFF group.
Echocardiographic measures of LV diastolic function did
not change significantly between groups from baseline to 1
year Table 2). Improvement in diastolic function in respond-
ers to CRT is poorly understood but is believed to be due in
part to “reverse molecular remodeling,” typified by enhanced
expression of calcium regulatory proteins. Also, in NYHA
Table 1. Baseline Demographics
Parameter
CRT-OFF
(n5191)
CRT-ON
(n5419) P
Age, y 61.8611.6 62.9610.6 0.26
Male 152 (80) 327 (78) 0.75
NYHA classification (class II) 159 (83) 344 (82) 0.82
Ischemic HF 97 (51) 236 (56) 0.22
Diabetic 46 (24) 91 (22) 0.53
ACE inhibitors or ARBs 186 (97) 404 (96) 0.63
b-Blockers 179 (94) 401 (96) 0.32
Diuretics 148 (77) 339 (81) 0.33
QRS width, ms 154624 153621 0.41
LVEF, % 26.467.1 26.867.0 0.50
LVESVi, mL/m2 102643 99635 0.51
Heart rate, bpm 68.2610.9 66.9610.3 0.17
Supine systolic blood pressure, mm Hg 123619 125619 0.25
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor
blocker.
Values are mean6SD or n (%).
P values are 2-sided and were calculated with Fisher exact test or the
2-sample t test.
Figure 1. Time course of changes in echocardiographic esti-
mates of LV volumes, dimensions, and ejection fraction in the
CRT-ON and CRT-OFF groups. Baseline values were obtained
before device implantation, after which CRT was either on at all
subsequent time points or off at all subsequent time points.
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class I/II patients with systolic heart failure, diastolic dys-
function is not as advanced as it is in NYHA III/IV, so there
is less substrate for improvement with CRT.
Early Transitory Changes Compared With
Sustained Long-Term Changes
The first echocardiogram at PHD was performed with CRT
turned off. The second echocardiogram was obtained after the
CRT device was turned on and the device settings had been
optimized. There were small but statistically significant early
changes in LV volumes, LVEF, myocardial performance
index, duration of LV filling, and the severity of MR when
CRT was turned on at PHD (Table 4); however, these
immediate changes in LV volumes and LVEF that occurred at
PHD did not correlate with the corresponding changes in
LVESVi (r50.11, P50.31), LVEDVi (r50.10, P50.38), or
LVEF (r50.07, P50.72) that occurred between PHD and 12
months. Importantly, switching from CRT turned on to CRT off
at 12 months did not result in any significant changes in LV
volumes, MR, or myocardial performance index (Table 4).
Effect of HF Origin
CRT improved LV performance in both patients with ische-
mic HF and those with nonischemic HF, but the magnitude of
improvements differed significantly between the 2 causes in
favor of the nonischemic patients (Table 5). There was a
3-fold greater reduction in LVEDVi and LVESVi in
CRT-ON patients with a nonischemic versus ischemic origin
of HF from baseline to 12 months. There was also a more
than 3-fold increase in LVEF in patients with a nonischemic
versus an ischemic cause of HF at 12 months. In addition,
regardless of the cutoff (5%, 15%, or 30% improvement),
nonischemic CRT-ON patients improved more than any other
group (Figure 2). When nonischemic and ischemic patients
were compared, more than twice the percentage of CRT-ON
patients had a .30% improvement compared with CRT-OFF
patients. This included 52% of nonischemic HF CRT-ON
patients and 20% of ischemic HF CRT-OFF patients with
.30% improvement in LVESVi versus 15% and 7% of
CRT-OFF patients with nonischemic and ischemic HF, re-
spectively (Figure 2).
IVMD and QRS Duration in Relation to
Reverse Remodeling
IVMD was divided into 3 groups (240 ms or less; 240 to 40
ms; and .40 ms). This categorical variable, along with
randomization, was used in a 2-way ANOVA. Randomiza-
tion (P,0.0001), category of IVMD (P,0.0001), and their
interaction (P50.0003) were all significant factors, because
there was a significant gradient in the reduction in LVESVi
with an increase in IVMD (Figure 3). Similarly, QRS
duration was divided into 3 groups (#140 ms; .140 to #160
ms; and .160 ms). In another ANOVA model, randomiza-
tion (P,0.0001), QRS width (P,0.0001), and their interac-
tion (P,0.0001) were also significant predictors of change in
LVESVi (Figure 3).
Discussion
CRT has proved efficacious in the treatment of NYHA III/IV
class HF patients who are refractory to medical therapy by
inducing LV reverse remodeling that improves survival.18
Optimal medical therapy attenuates LV remodeling, with
CRT providing additive reverse LV remodeling that is evi-
dent from the lack of change in mean LV volumes or mean
LVEF in the control (CRT-OFF) group in REVERSE at 1
year. This additional LV reverse remodeling in the CRT-ON
group occurred in spite of optimizing and stabilizing HF
treatment before study participation. Ninety-seven percent of
patients were taking angiotensin-converting enzyme inhibi-
tors or angiotensin II receptor blockers and 95% were taking
b-blockers in REVERSE. The lack of LV reverse remodeling
in the control group in REVERSE is corroborated by CRT
trials in advanced HF (NYHA class III/IV) in patients
Table 2. Echocardiographic Parameters Between CRT-ON and
CRT-OFF Groups at Baseline and 12 Months
Parameter Baseline 6 Months 12 Months
LVESVi, mL/m2
CRT-OFF 102643 (179) 100645 (175) 100649 (172)
CRT-ON 99635 (386) 85636 (376) 80635* (367)
LVEDVi, mL/m2
CRT-OFF 136647 (179) 135649 (175) 135654 (172)
CRT-ON 135641 (386) 119641 (376) 114640* (367)
LVEF, %
CRT-OFF 26.466.7 (179) 27.167.3 (175) 27.067.1 (172)
CRT-ON 27.266.6 (386) 30.768.4 (376) 31.868.8* (367)
LVESD, cm
CRT-OFF 5.7961.09 (141) 5.9161.10 (120) 5.8061.27 (114)
CRT-ON 5.7361.04 (271) 5.3861.15 (278) 5.2761.15* (252)
LVEDD, cm
CRT-OFF 6.9760.93 (141) 7.0361.04 (120) 6.9261.12 (115)
CRT-ON 6.9260.94 (271) 6.6161.04 (278) 6.5161.05* (253)
MR, %
CRT-OFF 16.1613.0 (123) 15.1613.6 (133) 15.9612.7 (124)
CRT-ON 15.1611.5 (273) 12.5610.8 (254) 13.1611.5 (240)
LV mass, g
CRT-OFF 274678 (126) 281681 (121) 278680 (111)
CRT-ON 269676 (249) 258669 (261) 255670 (215)
IVMD, ms
CRT-OFF 33.6636.4 (166) 35.2641.1 (166) 32.6642.1 (155)
CRT-ON 33.9640.1 (348) 22.0636.8 (347) 22.2635.3* (328)
MPI
CRT-OFF 9346133 (163) 9626152 (163) 9396164 (154)
CRT-ON 9656134 (354) 9616146 (352) 9636147 (347)
LV cavity
shape—diastole
CRT-OFF 0.5460.12 (179) 0.5560.12 (175) 0.5360.13 (172)
CRT-ON 0.5360.12 (386) 0.5060.12 (376) 0.4860.12* (367)
LVESD indicates LV end-systolic diameter; LVEDD, LV end-diastolic diame-
ter; and MPI, myocardial performance index.
Values in the table are mean6SD (n). Baseline values were recorded before
implantation. Six-month and 12-month values were recorded with the patients
in their randomized CRT mode.
*Between group P for change from baseline ,0.01.
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randomized to CRT-OFF.16 This is not to de-emphasize the
important role of angiotensin-converting enzyme inhibitors,
angiotensin II receptor blockers, and b-blockers, without
which patients develop progressive LV dilatation, distortion
of LV shape, and deteriorating function that culminates in
worsening HF or arrhythmic death.19,20
Little is known about the potential use of CRT in patients
with NYHA class I/II HF.6 REVERSE demonstrated for the
first time in a large, multicenter, randomized, double-blind,
controlled study that CRT results in significant LV reverse
remodeling, with changes in LV volumes and LVEF in
NYHA class I/II HF patients comparable to those seen in
NYHA class III/IV patients.21 The favorable changes in LV
volumes, shape, and LVEF with reverse remodeling occurred
only in the CRT-ON group and not in the CRT-OFF group.
Furthermore, LVEDVi and LVESVi in the CRT-ON group
continued to diverge from the CRT-OFF group through 1
year, which indicates that LV reverse remodeling likely
continues beyond 1 year, similar to findings in the CArdiac
REsynchronization in Heart Failure (CARE-HF) trial.17 Thus,
CRT may remarkably delay or even stop the natural disease
progression in patients with NYHA class I/II symptoms.
There are important clinical implications of retarding the
progression of NYHA class I/II to NYHA class III/IV HF by
reverse remodeling with CRT.15 These findings may be
confirmed by ongoing trials in this same patient popula-
tion.22,23 Unlike the significant decrease in LV mass that
occurred at 1 year in patients in NYHA class III/IV in
MIRACLE (Multicenter InSync Randomized Clinical Eval-
uation), there was no change in LV mass in the NYHA class
I/II HF patients in REVERSE at 12 months.21 The decrease in
LV volume without change in LV mass predictably lowered
end-systolic wall stress, because there was no change in LV
systolic pressure. Wall stress is a major determinant of LV
architecture, myocardial composition, and function. Although
the changes in biochemistry and electromechanical coupling
with CRT have not been completely elucidated, downregula-
tion of wall stress by CRT may be 1 mechanism that drives
Table 3. Comparison of Changes in Echocardiographic Parameters in the Same CRT Mode
Parameter
Baseline (CRT Not
Yet Implanted)
12 Months
CRT-OFF Paired Difference P PHD CRT-ON
12 Months
CRT-ON Paired Difference P
LVESVi, mL/m2 ,0.0001 ,0.0001
CRT-OFF 102643 (179) 100649 (172) 21.3623.4 (163) 99645 (158) 98645 (164) 20.2621.2 (142)
CRT-ON 99635 (386) 81636 (348) 218.4629.5 (324) 97635 (359) 80635 (367) 215.6627.3 (320)
LVEDVi, mL/m2 ,0.0001 ,0.0001
CRT-OFF 136647 (179) 135654 (172) 21.4628.0 (163) 135651 (158) 132650 (164) 21.9624.0 (142)
CRT-ON 135641 (386) 114641 (348) 220.5633.4 (324) 134639 (359) 114640 (367) 217.9630.4 (320)
LVEF, % ,0.0001 ,0.0001
CRT-OFF 26.466.7 (179) 27.067.1 (172) 0.666.5 (163) 27.866.7 (158) 27.167.1 (164) 20.866.5 (142)
CRT-ON 27.266.6 (386) 30.868.7 (348) 3.869.3 (324) 28.767.1 (359) 31.868.8 (367) 3.069.2 (320)
The columns on the left present between-group comparisons of changes in echocardiographic parameters from baseline (before CRT was implanted) to CRT turned
off at 12 months after either 12 months of biventricular pacing (CRT-ON group) or no biventricular pacing (CRT-OFF group). The columns on the right present
between-group comparisons of changes in echocardiographic parameters from PHD (when CRT was on) to CRT turned on at 12 months after either 12 months of
biventricular pacing (CRT-ON group) or no biventricular pacing (CRT-OFF group).
P values compare paired differences between CRT-OFF and CRT-ON (2-sample t test).
Table 4. Immediate Changes in Echocardiographic Parameters When CRT Mode Is Changed
All Patients: Parameters at PHD: Comparison
of CRT-OFF vs CRT-ON Echocardiograms
(Immediate Effects of Turning CRT-ON)
CRT-ON Patients Only: Parameters at
12 Months (Immediate Effects After
10-Minute “Washout” of Turning CRT-OFF)
n CRT-OFF to CRT-ON (95% CI) P n CRT-ON to CRT-OFF (95% CI) P
LVESVi, mL/m2 507 22.93610.62 (23.86, 22.01) ,0.0001 343 0.75610.45 (20.35, 1.86) 0.18
LVEDVi, mL/m2 507 21.21612.37 (22.29, 20.13) 0.03 343 20.25612.53 (21.58, 1.08) 0.71
LVEF, % 507 1.4464.39 (1.05, 1.82) ,0.0001 343 20.9865.87 (21.60, 20.35) 0.002
MR, % 432 21.1469.57 (22.04, 20.23) 0.01 283 0.4568.31 (20.52, 1.42) 0.36
LV filling time/R to R
interval, %
482 3.3667.06 (2.73, 3.99) ,0.0001 332 23.2967.19 (24.07, 22.52) ,0.0001
Myocardial performance
index
464 8.34666.92 (2.24, 14.45) 0.007 315 2.37683.38 (26.87, 11.62) 0.61
LV inflow, deceleration
time, ms
428 9.68655.27 (4.43, 14.94) 0.0003 317 27.38657.67 (213.75, 21.00) 0.02
The columns on the left report immediate (mean) changes in echocardiographic parameters that occurred from PHD before CRT was turned on to after CRT was
turned on at PHD. The columns on the right report mean changes in echocardiographic parameters that occurred only in CRT-ON patients at 12 months after a
10-minute washout of turning CRT off. Values are mean6SD.
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the LV reverse-remodeling process. Wall stress also modu-
lates the portfolio of stretch-activated matrix metalloprotein-
ases that regulate the extracellular cellular collagen scaffold
and facilitate changes in LV size.24
Another possible pathogenic mechanism for LV reverse
remodeling was the reduction in dyssynchrony between
baseline and 12 months. Evidence for decreased interventric-
ular dyssynchrony was provided by the decrease in isovolu-
mic contraction time and IVMD that occurred together with
the prolonged, heart rate–adjusted LV filling time observed
only in CRT-ON patients. Furthermore, there was a direct
relationship between baseline IVMD and the extent of LV
reverse remodeling. There was a similar relationship between
baseline QRS duration and reduction in LVESVi, which
indicates that the greater the global or interventricular dys-
synchrony, the greater the propensity for LV reverse remod-
eling and the potential for clinical benefit.5,14 Reduction in
MR could not be implicated as a major cause of reverse LV
remodeling in NYHA class I/II HF, because MR was present
in only a minority of patients, was mild, and did not change
in severity from baseline to 12 months.
The rationale for recording 2 echocardiograms (1 with
CRT programmed on and a second with CRT programmed
Table 5. Relationship of HF Origin to Remodeling at 12 Months by CRT Group
Nonischemic Cause of HF Ischemic Cause of HF ANOVA
Parameter CRT-OFF CRT-ON CRT-OFF CRT-ON Randomization Origin/Cause Interaction
LVESVi, mL/m2 26.6 (75) 229.7 (149) 3.2 (88) 29.6 (191) ,0.0001 ,0.0001 0.04
LVEDVi, mL/m2 27.9 (75) 230.5 (149) 4.2 (88) 210.7 (191) ,0.0001 ,0.0001 0.18
LVEF, % 1.12 (75) 7.61 (149) 0.24 (88) 2.24 (191) ,0.0001 ,0.0001 0.004
MR, % 1.05 (59) 21.90 (106) 0.47 (72) 20.80 (166) 0.07 0.82 0.47
LV mass, g 29.3 (47) 224.1 (73) 25.9 (48) 211.5 (98) 0.12 0.22 0.48
IVMD, ms 2.3 (72) 216.0 (114) 22.0 (68) 210.9 (162) 0.001 0.91 0.26
LV inflow, deceleration time, ms 4.1 (59) 24.6 (120) 24.5 (79) 28.24 (183) 0.34 0.02 0.17
Peak E/peak A 20.12 (60) 20.04 (127) 0.00 (82) 20.05 (184) 0.86 0.39 0.36
LV cavity shape—diastole 20.02 (75) 20.07 (149) 0.00 (88) 20.03 (191) 0.0003 0.008 0.33
The first 4 columns show the mean change from baseline to 12 months. The final 3 columns show the P values from an ANOVA with randomization, cause, and
the interaction between randomization and cause of HF in the model. A significant interaction term indicates that the difference between CRT-OFF and CRT-ON is
different between the ischemic and nonischemic populations. In addition, the change in LV cavity shape was greater in nonischemic patients.
Figure 2. Effect of HF origin on LVESVi, LVEDVi, and LVEF; rela-
tive changes from baseline to 12 months. The percent of
patients who improved with CRT and the magnitude of improve-
ment at 3 arbitrarily chosen levels (5%, 15%, and 30%) are
shown.
Figure 3. Relationship between IVMD and reduction in LVESVi
(above) and between QRS duration and reduction in LVESVi
(below) between CRT-ON and CRT-OFF groups. Mean6SD val-
ues are presented. P values are between groups (CRT-ON vs
CRT-OFF) and are not adjusted for multiple comparisons. With
Bonferroni correction for multiple comparisons, P values should
be ,0.05/350.0167 to be considered statistically significant.
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off) at PHD and at 12 months was to discriminate between
early transitory changes in LV volumes and LVEF and true
sustained reverse LV remodeling. At PHD, there were sig-
nificant early changes in LV dimensions, LV volumes,
LVEF, and severity of MR (Table 4); however, these early
changes in LV volumes and LVEF did not correlate with the
changes in LVESVi at 12 months. In contrast, dramatic
changes in LV volumes, LVEF, and MR were not observed at
12 months when CRT was turned off (Table 4), which
indicates that by 1 year, the LV reverse remodeling with CRT
had become sustained.
Approximately half of the patients in REVERSE (333/610,
54.5%) had HF due to ischemic heart disease, whereas 45.5%
had HF of a nonischemic origin. Studies in patients with
advanced HF have demonstrated differences in the reverse-
remodeling response to CRT according to the cause of HF.21
We demonstrated in REVERSE that CRT confers a 3-fold
greater change in LV volumes and LVEF at 12 months in
patients with nonischemic versus ischemic HF origin. These
observations parallel findings in patients in NYHA class
III/IV HF reported first in the MIRACLE trial21 and likely
represent a complement of irreversibly damaged ischemic
myocytes that respond less to CRT.
Study Limitations
A potential limitation of the present study is found in the
incomplete sets of echocardiographic linear measurements of
LV end-diastolic and end-systolic dimensions, which
amounted to approximately 50% of paired dimensions at
baseline and at 12 months; however, the paired data for LV
volumes were larger, and the significance and directional
changes in LV dimensions and LV volumes between baseline
and 12 months were concordant. Another potential limitation
of the present study was the choice of a 10-minute “washout”
period between the first of 2 echocardiograms performed at
12 months in patients randomized to CRT-ON. The first
echocardiogram was obtained in these patients with the CRT
device turned on and a second with it programmed off. The
arbitrary 10-minute washout period was to demonstrate that
changes in LV volumes did not revert to baseline values when
CRT was turned off but instead were sustained, which reflects
true reverse remodeling. Although there were no significant
changes in LV volumes after a 10-minute washout period in
the present study, such changes in volume may have occurred
if we had chosen a washout period of 1 day or 1 week.
In conclusion, REVERSE shows for the first time that
patients with NYHA class I/II HF respond to CRT similarly
to those with NYHA class III/IV HF because of LV reverse
remodeling. CRT resulted in favorable changes in LV archi-
tecture and function that occurred almost exclusively in
CRT-ON patients, although both patient groups were given
stable optimal medical therapy, often at target doses. The
present findings that CRT provides incremental LV reverse
remodeling compared with optimal medical therapy in
NYHA class I/II HF may have important clinical implications
in that CRT may delay or permanently interrupt the natural
disease progression in these patients. This and ongoing
studies may define an important therapeutic role for CRT in
patients with NYHA class I/II HF, especially those with a
nonischemic origin of HF.21,24
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CLINICAL PERSPECTIVE
Cardiac resynchronization therapy (CRT) has proved efficacious in New York Heart Association (NYHA) class III/IV
heart failure (HF). This key echocardiographic study assessed the impact of CRT on structural and functional reverse
remodeling in patients with NYHA class I/II HF. The REsynchronization reVErses Remodeling in Systolic left vEntricular
dysfunction (REVERSE) trial was a large, prospective, double-blind, controlled trial of CRT in patients with NYHA class
I/II HF, a QRS $120 ms, left ventricular (LV) end-diastolic dimension $55 mm, and LV ejection fraction #40% who were
randomly assigned to active therapy (CRT-on; n5419) or control (CRT-off; n5191). Doppler echocardiograms were
recorded at baseline, before hospital discharge, and at 6 and 12 months. The present study showed that CRT in patients
with NYHA class I/II HF who were already receiving optimal therapy with a b-blocker (95%), angiotensin-converting
enzyme inhibitor, or angiotensin receptor blocker (97%) resulted in LV reverse remodeling with favorable changes in LV
volume, shape, and ejection fraction similar to those that occurred in patients in NYHA class III/IV; however, there were
no accompanying changes in LV diastolic function, LV mass, or severity of mitral regurgitation. There was 3-fold greater
LV reverse remodeling in patients with a nonischemic origin of HF than in those with an ischemic origin. Our findings have
potentially important clinical implications in that CRT may delay or interrupt the natural disease progression of HF in these
patients. This and ongoing studies may define an important therapeutic role for CRT in patients with NYHA class I/II, as
well as class III/IV HF, especially those cases with a nonischemic cause.
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